pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
548
stories
10h
Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
biospace
2d
What it’s like to wait for the call from the Nobel Prize committee
stat
2d
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
biopharma dive
2d
Access to addiction meds for young people has improved — but retention hasn’t
stat
3d
An Ebola treatment center was burned down as the death toll in Congo passes 4,000
stat
3d
STAT+: Up and down the ladder: The latest comings and goings
stat
3d
STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more
stat
3d
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
biospace
3d
#EASD26: Regeneron sees a future combining its obesity drug with lipid-lowering therapy
endpoints
3d
Mistrust in science and a juicy gene-editing lawsuit
stat
3d
3 takeaways from a European obesity scientific meeting
biopharma dive
3d
As CDC redesigns annual health survey, it removes questions about disabilities
stat
4d
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
biospace
4d
#EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapy
endpoints
4d
STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more
stat
4d
Trump administration appeals ruling blocking limits on international student visas
stat
4d
Kallyope rebrands after Novo obesity deal, gets $94M for Phase 3 migraine drug
endpoints
4d
Opinion: I studied GLP-1 use in children. The results are reassuring
stat
4d
#EASD26: Boehringer's weight loss candidate trails rivals in diabetes and obesity
endpoints
4d
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
fiercebiotech
5d
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
5d
#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
endpoints
5d
STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
stat
5d
STAT+: Three biotech updates, including accusations of theft and and a new lobbying leader
stat
5d
STAT+: Pharmalittle: We’re reading about Beam suing over IP theft, a Trump rule on importing meds, and more
stat
5d
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
5d
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
5d
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program
fiercebiotech
5d
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
fiercebiotech
5d
#EASD26: Zealand and Roche's amylin works best at middle dose, trails Lilly's
endpoints
← prev
page 1 of 19
next →
